869:
812:
106:
293:
910:
160:
133:
853:
585:
581:
183:
166:
631:
577:
286:
903:
752:
668:
944:
279:
252:
221:
31:), is the proportion of incidents in the population that could be prevented by exposing the whole population. It is calculated as
896:
790:
203:
635:
357:
468:
846:
783:
868:
762:
934:
726:
698:
627:
381:
776:
452:
178:
165:
It is used when an exposure reduces the risk, as opposed to increasing it, in which case its symmetrical notion is
939:
571:
34:
839:
509:
457:
337:
597:
555:
533:
503:
403:
347:
330:
706:
464:
543:
929:
547:
434:
425:
372:
342:
306:
811:
513:
420:
352:
876:
673:
623:
438:
367:
325:
747:
711:
678:
603:
525:
302:
258:
248:
217:
880:
823:
521:
442:
396:
391:
271:
209:
213:
138:
111:
716:
539:
494:
742:
663:
615:
408:
320:
923:
721:
688:
683:
563:
447:
20:
757:
611:
484:
474:
819:
559:
551:
517:
479:
386:
262:
619:
607:
653:
658:
247:(3rd ed.). Philadelphia: Lippincott Williams & Wilkins.
243:
Rothman, Kenneth J.; Greenland, Sander; Lash, Timothy L. (2012).
275:
202:
884:
827:
141:
114:
37:
735:
697:
646:
596:
570:
532:
502:
493:
419:
366:
313:
154:
127:
100:
904:
847:
287:
205:Dictionary of Epidemiology - Oxford Reference
8:
911:
897:
854:
840:
499:
294:
280:
272:
101:{\displaystyle PF_{p}=(I_{p}-I_{e})/I_{p}}
146:
140:
119:
113:
92:
83:
74:
61:
45:
36:
586:Preventable fraction among the unexposed
582:Attributable fraction for the population
208:. Oxford University Press. p. 223.
184:Preventable fraction among the unexposed
167:attributable fraction for the population
590:Preventable fraction for the population
578:Attributable fraction among the exposed
194:
135:is the incidence in the exposed group,
25:preventable fraction for the population
162:is the incidence in the population.
7:
865:
863:
808:
806:
753:Correlation does not imply causation
669:Animal testing on non-human primates
214:10.1093/acref/9780199976720.001.0001
883:. You can help Knowledge (XXG) by
826:. You can help Knowledge (XXG) by
14:
867:
810:
636:Pre- and post-test probability
358:Patient and public involvement
80:
54:
1:
763:Sex as a biological variable
16:Measure used in epidemiology
727:Intention-to-treat analysis
699:Analysis of clinical trials
628:Specificity and sensitivity
382:Randomized controlled trial
961:
862:
805:
179:Population Impact Measures
771:
736:Interpretation of results
469:Nested case–control study
945:Health informatics stubs
875:This article related to
338:Academic clinical trials
556:Relative risk reduction
404:Adaptive clinical trial
348:Evidence-based medicine
331:Adaptive clinical trial
822:-related article is a
544:Number needed to treat
156:
129:
102:
548:Number needed to harm
435:Cross-sectional study
387:Scientific experiment
343:Clinical study design
157:
155:{\displaystyle I_{p}}
130:
128:{\displaystyle I_{e}}
103:
514:Cumulative incidence
139:
112:
35:
421:Observational study
353:Real world evidence
307:experimental design
245:Modern epidemiology
935:Medical statistics
877:health informatics
707:Risk–benefit ratio
674:First-in-man study
624:Case fatality rate
465:Case–control study
439:Longitudinal study
152:
125:
98:
892:
891:
835:
834:
800:
799:
748:Survivorship bias
712:Systematic review
679:Multicenter trial
642:
641:
632:Likelihood-ratios
604:Clinical endpoint
572:Population impact
526:Period prevalence
303:Clinical research
30:
952:
940:Statistics stubs
913:
906:
899:
871:
864:
856:
849:
842:
814:
807:
647:Trial/test types
522:Point prevalence
500:
443:Ecological study
426:EBM II-2 to II-3
397:Open-label trial
392:Blind experiment
368:Controlled study
296:
289:
282:
273:
267:
266:
240:
234:
233:
231:
230:
199:
161:
159:
158:
153:
151:
150:
134:
132:
131:
126:
124:
123:
107:
105:
104:
99:
97:
96:
87:
79:
78:
66:
65:
50:
49:
28:
960:
959:
955:
954:
953:
951:
950:
949:
920:
919:
918:
917:
861:
860:
803:
801:
796:
767:
731:
693:
638:
592:
566:
540:Risk difference
528:
489:
423:
415:
370:
362:
326:Trial protocols
309:
300:
270:
255:
242:
241:
237:
228:
226:
224:
201:
200:
196:
192:
175:
142:
137:
136:
115:
110:
109:
88:
70:
57:
41:
33:
32:
17:
12:
11:
5:
958:
956:
948:
947:
942:
937:
932:
922:
921:
916:
915:
908:
901:
893:
890:
889:
872:
859:
858:
851:
844:
836:
833:
832:
815:
798:
797:
795:
794:
791:List of topics
787:
780:
772:
769:
768:
766:
765:
760:
755:
750:
745:
743:Selection bias
739:
737:
733:
732:
730:
729:
724:
719:
714:
709:
703:
701:
695:
694:
692:
691:
686:
681:
676:
671:
666:
664:Animal testing
661:
656:
650:
648:
644:
643:
640:
639:
616:Mortality rate
602:
600:
594:
593:
576:
574:
568:
567:
538:
536:
530:
529:
508:
506:
497:
491:
490:
488:
487:
482:
477:
472:
462:
461:
460:
455:
445:
431:
429:
417:
416:
414:
413:
412:
411:
409:Platform trial
401:
400:
399:
394:
389:
378:
376:
364:
363:
361:
360:
355:
350:
345:
340:
335:
334:
333:
328:
321:Clinical trial
317:
315:
311:
310:
301:
299:
298:
291:
284:
276:
269:
268:
253:
235:
222:
193:
191:
188:
187:
186:
181:
174:
171:
149:
145:
122:
118:
95:
91:
86:
82:
77:
73:
69:
64:
60:
56:
53:
48:
44:
40:
15:
13:
10:
9:
6:
4:
3:
2:
957:
946:
943:
941:
938:
936:
933:
931:
928:
927:
925:
914:
909:
907:
902:
900:
895:
894:
888:
886:
882:
878:
873:
870:
866:
857:
852:
850:
845:
843:
838:
837:
831:
829:
825:
821:
816:
813:
809:
804:
793:
792:
788:
786:
785:
781:
779:
778:
774:
773:
770:
764:
761:
759:
756:
754:
751:
749:
746:
744:
741:
740:
738:
734:
728:
725:
723:
722:Meta-analysis
720:
718:
715:
713:
710:
708:
705:
704:
702:
700:
696:
690:
689:Vaccine trial
687:
685:
684:Seeding trial
682:
680:
677:
675:
672:
670:
667:
665:
662:
660:
657:
655:
652:
651:
649:
645:
637:
633:
629:
625:
621:
617:
613:
609:
605:
601:
599:
595:
591:
587:
583:
579:
575:
573:
569:
565:
561:
557:
553:
549:
545:
541:
537:
535:
531:
527:
523:
519:
515:
511:
507:
505:
501:
498:
496:
492:
486:
483:
481:
478:
476:
473:
470:
466:
463:
459:
456:
454:
453:Retrospective
451:
450:
449:
446:
444:
440:
436:
433:
432:
430:
427:
422:
418:
410:
407:
406:
405:
402:
398:
395:
393:
390:
388:
385:
384:
383:
380:
379:
377:
374:
373:EBM I to II-1
369:
365:
359:
356:
354:
351:
349:
346:
344:
341:
339:
336:
332:
329:
327:
324:
323:
322:
319:
318:
316:
312:
308:
304:
297:
292:
290:
285:
283:
278:
277:
274:
264:
260:
256:
254:9780781755641
250:
246:
239:
236:
225:
223:9780199976720
219:
215:
211:
207:
206:
198:
195:
189:
185:
182:
180:
177:
176:
172:
170:
168:
163:
147:
143:
120:
116:
93:
89:
84:
75:
71:
67:
62:
58:
51:
46:
42:
38:
26:
22:
930:Epidemiology
885:expanding it
874:
828:expanding it
817:
802:
789:
782:
775:
589:
564:Hazard ratio
448:Cohort study
244:
238:
227:. Retrieved
204:
197:
164:
24:
21:epidemiology
18:
758:Null result
717:Replication
612:Infectivity
534:Association
485:Case report
475:Case series
458:Prospective
924:Categories
820:statistics
560:Odds ratio
552:Risk ratio
518:Prevalence
504:Occurrence
480:Case study
229:2018-05-09
190:References
620:Morbidity
608:Virulence
510:Incidence
263:169455558
68:−
784:Glossary
777:Category
654:In vitro
495:Measures
314:Overview
173:See also
108:, where
659:In vivo
261:
251:
220:
879:is a
818:This
598:Other
881:stub
824:stub
437:vs.
305:and
259:OCLC
249:ISBN
218:ISBN
210:doi
27:(PF
19:In
926::
634:,
630:,
626:,
622:,
618:,
614:,
610:,
606:,
588:,
584:,
580:,
562:,
558:,
554:,
550:,
546:,
542:,
524:,
520:,
516:,
512:,
441:,
257:.
216:.
169:.
23:,
912:e
905:t
898:v
887:.
855:e
848:t
841:v
830:.
471:)
467:(
428:)
424:(
375:)
371:(
295:e
288:t
281:v
265:.
232:.
212::
148:p
144:I
121:e
117:I
94:p
90:I
85:/
81:)
76:e
72:I
63:p
59:I
55:(
52:=
47:p
43:F
39:P
29:p
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.